In the present study, we examined the safety and efficacy of the oral administration of fragmented CP1563 on the depletion of body fat in a double-blinded, parallel group randomized clinical trial involving overweight and pre-obese subjects with a body mass index (BMI) ranging 25 or more but less than 30 kg/m2 (12, 13). Improvements in anthropometric measurements and markers were observed in obese class I subjects in the test group. This result suggests that the consumption of foods containing CP1563 reduces body fat and prevents metabolic syndrome.